Vigil Neuroscience, Inc. stock is down -60.45% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 November’s closed higher than October. 100% of analysts rate it a buy.
Vigil Neuroscience, Inc. engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) The company also develops a small molecule TREM2 agonist suitable for oral delivery.